Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Why this talk

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Apr 23, 2021 8:14am

106 Views

Post# 33053848

RE:Why this talk

StockingUp21 wrote:
Of new drugs when taken many years and drug 2 still no where near trials. I'm tired of hearing anything with date put forward when trust is gone.

Did not meet one timeline since I invested. No investor will care about this when its so far away.

Dan is tasked with marketing to new investors. I'm assuming that's what this is all about. New investors are virgins to delay - the past really doesn't matter to them, it's about what you represent for the future. For them to decide if this is a blockbuster or not.

Small steps forward !!!

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity